SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--BioSeek, Inc., a pioneer in the application of predictive human biology to drug discovery, announced today that it has signed a new, three-year collaboration agreement with Merck KGaA, Darmstadt, Germany, acting for its division Merck Serono, extending and expanding the companies’ previous 2008 compound profiling agreement. Under the research plan, BioSeek will continue to use its proprietary BioMAP platform to evaluate Merck Serono small molecule compounds and proteins across multiple therapeutic areas in support of target differentiation, lead selection, and nomination of candidates for preclinical development at Merck Serono. Financial details were not disclosed.
